Dallas, Texas
Colorectal cancer clinical trials in Dallas, TX
46 colorectal cancer studies are recruiting participants at sites in Dallas as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Dallas at a glance
- 46 studies are recruiting at a site in Dallas.
- By phase: Phase 1 (17), Phase 1/2 (13), Phase 2 (3), Phase 2/3 (2), Phase 3 (5), Phase 4 (2), Observational (4).
- By sponsor: industry (41), university, hospital or other (5).
- Most recent update to one of these records: November 16, 2026.
Studies recruiting in Dallas
Basic details from each study's public record (the 30 most recently updated of 46). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Parkland Memorial Hospital · UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
- Registry record
- NCT05863195 · updated
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Texas Oncology - DFW ( Site 8002) · UT Southwestern Medical Center ( Site 0059)
- Registry record
- NCT06997497 · updated
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT07228832 · updated
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- NRG Oncology
- Study sites
- Parkland Memorial Hospital · UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
- Registry record
- NCT05174169 · updated
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Jazz Pharmaceuticals
- Study site
- Texas Oncology - DFW
- Registry record
- NCT06695845 · updated
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Texas Oncology - DFW (Sammons CC)
- Registry record
- NCT07213791 · updated
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Sairopa B.V.
- Study site
- University of Texas Southwestern Medical Center
- Registry record
- NCT05856981 · updated
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study sites
- Texas Oncology DFW · UT Southwestern
- Registry record
- NCT06662786 · updated
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study sites
- Parkland Health and Hospital System · Texas Oncology DFW · UT Southwestern Medical Center
- Registry record
- NCT06750094 · updated
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kumquat Biosciences Inc.
- Study site
- START Dallas Fort Worth
- Registry record
- NCT07542704 · updated
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Genmab
- Study site
- Texas Oncology
- Registry record
- NCT03526835 · updated
Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Phase 1/2
- Ages 18 to 90
- All sexes
- Sponsor
- Perspective Therapeutics
- Study site
- UT Southwestern University Hospital Radiology Clinic
- Registry record
- NCT06710756 · updated
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- Phase 1/2
- Ages 18 to 80
- All sexes
- Sponsor
- Blue Earth Diagnostics
- Study site
- University of Texas Southwestern Medical Center
- Registry record
- NCT07432633 · updated
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Daiichi Sankyo
- Study site
- Texas Oncology, P.A.
- Registry record
- NCT06330064 · updated
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Artios Pharma Ltd
- Study sites
- Mary Crowley Cancer Research · University of Texas Southwestern
- Registry record
- NCT04657068 · updated
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kura Oncology, Inc.
- Study site
- UT Southwestern Simmons Cancer Center
- Registry record
- NCT06026410 · updated
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- PMV Pharmaceuticals, Inc
- Study site
- UT Southwest Simmons Cancer Center
- Registry record
- NCT04585750 · updated
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Exelixis
- Study site
- Exelixis Clinical Site #89
- Registry record
- NCT05176483 · updated
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Study sites
- SCRI at Mary Crowley · University of Texas Southwestern Medical Center
- Registry record
- NCT06625775 · updated
DESTINY-PANTUMOUR04
- Observational
- Ages 18 to 130
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT07124000 · updated
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- GlaxoSmithKline
- Study site
- GSK Investigational Site
- Registry record
- NCT07277270 · updated
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Neonc Technologies, Inc.
- Study site
- Baylor, Scott and White Research Institute
- Registry record
- NCT06047379 · updated
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- NEXT - Dallas
- Registry record
- NCT07349537 · updated
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- Guardant Health, Inc.
- Study site
- UT Southwestern Medical Center
- Registry record
- NCT05059444 · updated
A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Iambic Therapeutics, Inc
- Study site
- Mary Crowley Cancer Research
- Registry record
- NCT06253871 · updated
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Stingray Therapeutics
- Study site
- Texas Oncology- Sammons- DFW
- Registry record
- NCT06589440 · updated
A Study of ASP1002 in Adults for Treatment of Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- Mary Crowley Cancer Research Center
- Registry record
- NCT05719558 · updated
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
- Phase 4
- Ages 18 and older
- All sexes
- Sponsor
- Takeda
- Study site
- University of Texas Southwestern Medical Center
- Registry record
- NCT06562543 · updated
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pilatus Biosciences Inc
- Study site
- NEXT Dallas
- Registry record
- NCT07337525 · updated
Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery
- Phase 2/3
- Ages 18 to 80
- All sexes
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
- Study site
- UT Southwestern Medical Center
- Registry record
- NCT03051464 · updated
Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Dallas, TX on ClinicalTrials.gov.
Ask about studies near Dallas
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Texas
All Texas locations
195 studies recruiting across 43 cities.
Houston
140 studies recruiting.
San Antonio
53 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections